Synthesis and biological evaluation of diarylthiazole derivatives as antimitotic and antivascular agents with potent antitumor activity. 2015

Fang Wang, and Zhuang Yang, and Yibin Liu, and Liang Ma, and Yuzhe Wu, and Lin He, and Mingfeng Shao, and Kun Yu, and Wenshuang Wu, and Yuzhi Pu, and Chunlai Nie, and Lijuan Chen
State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, PR China.

By switching position of the N and S atom in the thiazole ring which were similar to the previously reported agent 5-(4-ethoxyphenyl)-4-(3',4',5'-trimethoxyphenyl)thiazol-2-amine, a series of 4,5-diarylthiazole derivatives were synthesized using Friedel-Crafts reaction based on chemical modification of Combrestatatin A-4 (CA-4). Their antiproliferative activities were evaluated and identified as new microtubule destabilizing agents. Structure-activity relationship study indicated that compound 8a with 3,4,5-trimethoxyphenyl group at the C-4 position and 4-ethoxyphenyl group at the C-5 position of 2-amino substituted thiazole was of the most potent inhibitory activity in this series. 8a was found to exhibit the IC50 values of 8.4-26.4nM in five human cancer cell lines, with comparable inhibition effects to CA-4. Moreover, 8a showed potency as a tubulin polymerization inhibitor, with colchicine site binding ability and comparable extent of inhibition against the growth of P-glycoprotein over-expressing multidrug resistant cell lines. Mechanism studies revealed that 8a could block the progression of cell cycle in the G2/M phase and result in cellular apoptosis in cancer cells. As a new tubulin destabilizing agent, 8a was also found high antivascular activity as it concentration-dependently reduced the cell migration and disrupted capillary like tube formation of HUVEC cells. Furthermore, 8a significantly suppressed the tumor growth in HCT116 and SK-OV-3 xenograft models with tumor growth inhibitory rate of 55.12% and 72.7%, respectively. Our studies highlighted that 8a was a promising microtubule targeting antitumor agent.

UI MeSH Term Description Entries
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D002465 Cell Movement The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell. Cell Migration,Locomotion, Cell,Migration, Cell,Motility, Cell,Movement, Cell,Cell Locomotion,Cell Motility,Cell Movements,Movements, Cell
D003078 Colchicine A major alkaloid from Colchicum autumnale L. and found also in other Colchicum species. Its primary therapeutic use is in the treatment of gout, but it has been used also in the therapy of familial Mediterranean fever (PERIODIC DISEASE). Colchicine, (+-)-Isomer,Colchicine, (R)-Isomer
D003110 Colonic Neoplasms Tumors or cancer of the COLON. Cancer of Colon,Colon Adenocarcinoma,Colon Cancer,Cancer of the Colon,Colon Neoplasms,Colonic Cancer,Neoplasms, Colonic,Adenocarcinoma, Colon,Adenocarcinomas, Colon,Cancer, Colon,Cancer, Colonic,Cancers, Colon,Cancers, Colonic,Colon Adenocarcinomas,Colon Cancers,Colon Neoplasm,Colonic Cancers,Colonic Neoplasm,Neoplasm, Colon,Neoplasm, Colonic,Neoplasms, Colon
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013267 Stilbenes Organic compounds that contain 1,2-diphenylethylene as a functional group. Stilbene,Stilbene Derivative,Stilbene Derivatives,Stilbenoid,Stilbenoids,Derivative, Stilbene,Derivatives, Stilbene

Related Publications

Fang Wang, and Zhuang Yang, and Yibin Liu, and Liang Ma, and Yuzhe Wu, and Lin He, and Mingfeng Shao, and Kun Yu, and Wenshuang Wu, and Yuzhi Pu, and Chunlai Nie, and Lijuan Chen
March 2014, Bioorganic & medicinal chemistry letters,
Fang Wang, and Zhuang Yang, and Yibin Liu, and Liang Ma, and Yuzhe Wu, and Lin He, and Mingfeng Shao, and Kun Yu, and Wenshuang Wu, and Yuzhi Pu, and Chunlai Nie, and Lijuan Chen
July 2005, Bioorganic & medicinal chemistry letters,
Fang Wang, and Zhuang Yang, and Yibin Liu, and Liang Ma, and Yuzhe Wu, and Lin He, and Mingfeng Shao, and Kun Yu, and Wenshuang Wu, and Yuzhi Pu, and Chunlai Nie, and Lijuan Chen
June 2009, Bioorganic & medicinal chemistry,
Fang Wang, and Zhuang Yang, and Yibin Liu, and Liang Ma, and Yuzhe Wu, and Lin He, and Mingfeng Shao, and Kun Yu, and Wenshuang Wu, and Yuzhi Pu, and Chunlai Nie, and Lijuan Chen
December 2022, Journal of enzyme inhibition and medicinal chemistry,
Fang Wang, and Zhuang Yang, and Yibin Liu, and Liang Ma, and Yuzhe Wu, and Lin He, and Mingfeng Shao, and Kun Yu, and Wenshuang Wu, and Yuzhi Pu, and Chunlai Nie, and Lijuan Chen
February 2017, European journal of medicinal chemistry,
Fang Wang, and Zhuang Yang, and Yibin Liu, and Liang Ma, and Yuzhe Wu, and Lin He, and Mingfeng Shao, and Kun Yu, and Wenshuang Wu, and Yuzhi Pu, and Chunlai Nie, and Lijuan Chen
September 2016, Journal of medicinal chemistry,
Fang Wang, and Zhuang Yang, and Yibin Liu, and Liang Ma, and Yuzhe Wu, and Lin He, and Mingfeng Shao, and Kun Yu, and Wenshuang Wu, and Yuzhi Pu, and Chunlai Nie, and Lijuan Chen
November 2020, Bioorganic chemistry,
Fang Wang, and Zhuang Yang, and Yibin Liu, and Liang Ma, and Yuzhe Wu, and Lin He, and Mingfeng Shao, and Kun Yu, and Wenshuang Wu, and Yuzhi Pu, and Chunlai Nie, and Lijuan Chen
August 2002, Bioorganic & medicinal chemistry letters,
Fang Wang, and Zhuang Yang, and Yibin Liu, and Liang Ma, and Yuzhe Wu, and Lin He, and Mingfeng Shao, and Kun Yu, and Wenshuang Wu, and Yuzhi Pu, and Chunlai Nie, and Lijuan Chen
October 2007, Bioorganic & medicinal chemistry letters,
Fang Wang, and Zhuang Yang, and Yibin Liu, and Liang Ma, and Yuzhe Wu, and Lin He, and Mingfeng Shao, and Kun Yu, and Wenshuang Wu, and Yuzhi Pu, and Chunlai Nie, and Lijuan Chen
April 2006, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!